JPRN-C000000408
Unknown
Phase 2
Gefitnib monotherapy in patients with post-operative recurrent non-small-cell lung cancer with the EGFR mutation: a Phase II study - Gefitnib monotherapy in patients with post-operative recurrent non-small-cell lung cancer with the EGFR mutation: a Phase II study
Okayama University Cancer and Thoracic Surgery0 sites40 target enrollmentApril 24, 2006
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- non small cell lung cancer with EGFR mutation
- Sponsor
- Okayama University Cancer and Thoracic Surgery
- Enrollment
- 40
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)EGFR mutations except exon19 deletion and exon21 mutation (L858R) or double mutation. 2\)Serious infectious disease 3\) Brain metastases requiring treatment 4\) Serious concomitant disease 5\) Ascites, pleural or pericardeal effusion requiring drainage 6\)Pregnant or lactation women, or women with known or suspected pregnancy 7\) Apparent ineterstitial pneumonia or pulmonary fibrosis 8\) Prior treatment of gefitinib 9\) Requiring emergency radiotherapy Cardiac infarction within 6 month 10\)Inappropriate patients for this study judged by the physicians
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Phase I/II study of Gefitnib monotherapy as neo-adjuvant chemotherapy for cN2 lung adenocarcinoma with the EGFR mutatioJPRN-UMIN000004807KantoKoshinetsu lung cancer research group20
Completed
Not Applicable
Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.non-small cell lung cancerJPRN-UMIN000000637Juntendo University, School of Medicine20
Completed
Phase 2
A Phase II Study of Gefitinib Monotherapy as First-Line Treatment for Elderly Patients with Stage IIIB /IV Adenocarcinoma of the LungJPRN-UMIN000006144Central Japan Lung Study Group32
Completed
Phase 2
Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT00824746Chonnam National University Hospital23
Recruiting
Not Applicable
Efficacy and safety of gefitinib monotherapy for all types of refractory cancer patients with EGFR amplificatioKCT0004066Samsung Medical Center3